Deutsche Bank Ag\ Aeterna Zentaris Inc. Transaction History

Deutsche Bank Ag\

  • $240 Billion
  • Q3 2024

Shares

18 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2021

Aug 11, 2021
SELL
$0.83 - $1.14 $28,220 - $38,760
-34,000 Closed
0 $0
Q1 2021

May 13, 2021
BUY
$0.51 - $3.34 $17,340 - $113,560
34,000 New
34,000 $38,000
Q4 2020

Feb 16, 2021
SELL
$0.3 - $0.44 $750 - $1,100
-2,500 Closed
0 $0
Q3 2020

Nov 12, 2020
BUY
$0.34 - $0.55 $850 - $1,375
2,500 New
2,500 $1,000
Q1 2020

May 14, 2020
SELL
$0.42 - $1.44 $3,696 - $12,674
-8,802 Closed
0 $0
Q4 2019

Feb 14, 2020
SELL
$0.77 - $1.08 $4,074 - $5,714
-5,291 Reduced 37.54%
8,802 $8,000
Q3 2019

Nov 14, 2019
SELL
$1.0 - $2.97 $81,707 - $242,669
-81,707 Reduced 85.29%
14,093 $14,000
Q2 2019

Aug 14, 2019
SELL
$2.04 - $5.43 $39,780 - $105,885
-19,500 Reduced 16.91%
95,800 $282,000
Q1 2019

May 15, 2019
BUY
$3.03 - $4.65 $276,639 - $424,545
91,300 Added 380.42%
115,300 $536,000
Q4 2018

Feb 14, 2019
BUY
$1.3 - $3.87 $2,600 - $7,740
2,000 Added 9.09%
24,000 $70,000
Q3 2018

Dec 21, 2021
SELL
$1.6 - $2.03 $17 - $22
-11 Reduced 0.05%
22,000 $38,000
Q3 2018

Nov 14, 2018
BUY
$1.6 - $2.03 $497 - $631
311 Added 1.43%
22,011 $38,000
Q2 2018

Apr 21, 2020
SELL
$1.19 - $2.62 $13 - $28
-11 Reduced 0.05%
21,700 $42,000
Q2 2018

Aug 14, 2018
SELL
$1.19 - $2.62 $1,890 - $4,163
-1,589 Reduced 6.82%
21,711 $42,000
Q1 2018

Oct 18, 2019
SELL
$1.46 - $2.41 $16 - $26
-11 Reduced 0.05%
23,300 $34,000
Q1 2018

May 15, 2018
SELL
$1.46 - $2.41 $24,638 - $40,671
-16,876 Reduced 41.99%
23,311 $34,000
Q4 2017

Feb 14, 2018
BUY
$1.87 - $2.7 $16,190 - $23,376
8,658 Added 27.46%
40,187 $94,000
Q3 2017

Nov 14, 2017
BUY
$1.81 - $2.23 $57,067 - $70,309
31,529
31,529 $64,000

About Aeterna Zentaris Inc.

AEZS Quotes by TradingView
  • Ticker AEZS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 4,855,880
  • Market Cap $19.4M
  • Description
  • Aeterna Zentaris Inc., a specialty biopharmaceutical company, engages in developing and commercializing therapeutics and diagnostic tests. Its lead product is macimorelin, an orally available peptidomimetic ghrelin receptor (GHSR-1a) agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a for the diagnosis of adult grow...
More about AEZS
Track This Portfolio

Track Deutsche Bank Ag\ Portfolio

Follow Deutsche Bank Ag\ and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Deutsche Bank Ag\, based on Form 13F filings with the SEC.

News

Stay updated on Deutsche Bank Ag\ with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email